Metronidazole resistance is a key factor associated with Helicobacter pylori treatment failure. Although this resistance is mainly associated with mutations in the rdxA and frxA genes, the question of whether metronidazole resistance is caused by the inactivation of frxA alone is still debated. Furthermore, it is unclear whether there are other mutations involved in addition to the two genes that are associated with resistance. A metronidazole-resistant strain was cultured from the metronidazole-susceptible H. pylori strain 26695-1 by exposure to low concentrations of metronidazole. The genome sequences of both susceptible and resistant H. pylori strains were determined by Illumina next-generation sequencing, from which putative candidate resistance mutations were identified. Natural transformation was used to introduce PCR products containing candidate mutations into the susceptible parent strain 26695-1, and the metronidazole MIC was determined for each strain. Mutations in frxA (hp0642), rdxA (hp0954), and rpsU (hp0562) were confirmed by the Sanger method. The mutated sequence in rdxA was successfully transformed into strain 26695-1, and the transformants showed resistance to metronidazole. The transformants containing a single mutation in rdxA showed a low MIC (16 mg/liter), while those containing mutations in both rdxA and frxA showed a higher MIC (48 mg/ liter). No transformants containing a single mutation in frxA or rpsU were obtained. Next-generation sequencing was used to identify mutations related to drug resistance. We confirmed that the mutations in rdxA are mainly associated with metronidazole resistance, and mutations in frxA are able to enhance H. pylori resistance only in the presence of rdxA mutations. Moreover, mutations in rpsU may play a role in metronidazole resistance.
Helicobacter pylori is a spiral-shaped Gram-negative bacterium that infects more than half of the world's population and is a major cause of chronic gastritis, peptic ulcer diseases, gastric cancer, and mucosa-associated lymphoid tissue lymphoma (1, 2). The eradication of H. pylori not only improves peptic ulcer healing but also prevents its recurrence and reduces the risk of developing gastric cancer (3-5). Furthermore, other H. pylori-related disorders, such as mucosa-associated lymphoid tissue lymphoma, atrophic gastritis, and intestinal metaplasia, have been shown to regress after antimicrobial therapy (6-8). Metronidazole has been used widely in combination therapies, such as metronidazolebased triple therapy, concomitant therapy, and bismuth-containing quadruple therapy, to eradicate this bacterium (5, 9, 10). Although treatment success depends on several factors, such as smoking status and patient compliance, antibiotic resistance is the major cause of treatment failure (11-13). However, along with clarithromycin resistance, resistance to metronidazole has arisen independently and is becoming increasingly common (14, 15).Resistance to metronidazole was described previously and is predominantly associated with mutation...